R Riisnaes
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
Bianchini D, de Bono J, Scher H, Attard G, Rathkopf D, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin A, Danila D. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 2013; 109:2579-86.
29.10.2013First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
29.10.2013Br J Cancer 2013; 109:2579-86
Bianchini D, de Bono J, Scher H I, Attard G, Rathkopf D E, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin Aurelius, Danila D C
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Sandhu S, Assiotis I, Olmos D, Yap T, Fong P, Tunariu N, Koh D, Molife L, Kaye S, Lord C, Ashworth A, Fenwick K, Campbell J, Omlin A, Hylands L, Miranda S, Barber L, Riisnaes R, Reid A, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24:1416-8.
22.03.2013Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
22.03.2013Ann Oncol 2013; 24:1416-8
Sandhu S K, Assiotis I, Olmos D, Yap T A, Fong P, Tunariu N, Koh D, Molife L R, Kaye S, Lord C J, Ashworth A, Fenwick K, Campbell J, Omlin Aurelius, Hylands L, Miranda S, Barber L J, Riisnaes R, Reid A H, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J